Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas

D Vallois, MPD Dobay, RD Morin… - Blood, The Journal …, 2016 - ashpublications.org
D Vallois, MPD Dobay, RD Morin, F Lemonnier, E Missiaglia, M Juilland, J Iwaszkiewicz…
Blood, The Journal of the American Society of Hematology, 2016ashpublications.org
Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from follicular T-
helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with
poorly understood pathogenesis and unfavorable treatment results. We investigated a series
of 85 patients with AITL (n= 72) or other TFH-derived PTCL (n= 13) by targeted deep
sequencing of a gene panel enriched in T-cell receptor (TCR) signaling elements. RHOA
mutations were identified in 51 of 85 cases (60%) consisting of the highly recurrent dominant …
Abstract
Angioimmunoblastic T-cell lymphoma (AITL) and other lymphomas derived from follicular T-helper cells (TFH) represent a large proportion of peripheral T-cell lymphomas (PTCLs) with poorly understood pathogenesis and unfavorable treatment results. We investigated a series of 85 patients with AITL (n = 72) or other TFH-derived PTCL (n = 13) by targeted deep sequencing of a gene panel enriched in T-cell receptor (TCR) signaling elements. RHOA mutations were identified in 51 of 85 cases (60%) consisting of the highly recurrent dominant negative G17V variant in most cases and a novel K18N in 3 cases, the latter showing activating properties in in vitro assays. Moreover, half of the patients carried virtually mutually exclusive mutations in other TCR-related genes, most frequently in PLCG1 (14.1%), CD28 (9.4%, exclusively in AITL), PI3K elements (7%), CTNNB1 (6%), and GTF2I (6%). Using in vitro assays in transfected cells, we demonstrated that 9 of 10 PLCG1 and 3 of 3 CARD11 variants induced MALT1 protease activity and increased transcription from NFAT or NF-κB response element reporters, respectively. Collectively, the vast majority of variants in TCR-related genes could be classified as gain-of-function. Accordingly, the samples with mutations in TCR-related genes other than RHOA had transcriptomic profiles enriched in signatures reflecting higher T-cell activation. Although no correlation with presenting clinical features nor significant impact on survival was observed, the presence of TCR-related mutations correlated with early disease progression. Thus, targeting of TCR-related events may hold promise for the treatment of TFH-derived lymphomas.
ashpublications.org